Zovegalisib

N/A

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameZovegalisib
Drug Alias NameRLY-2608
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsMetastatic breast cancerCLOVES SyndromeSolid tumours +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[23
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRelay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRelay Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCLOVES SyndromeSolid tumours +[9
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A